Page 19 - Biocon

Logging in with facemasks: Offices look different as staff returns to work

Office life in these cities resumed on Monday, albeit cautiously and with full knowledge of the need to maintain social distancing.

Will invest Rs 2k cr in small molecules segment in 3-4 yrs: Biocon CEO & MD

In a Q&A, Biocon CEO and MD Siddharth Mittal explains why he believes his company is on track to achieve the $1 billion revenue target from the segment by 2022

MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall

All that happened in the markets today

Biocon shares slump over 4% as profit declines 42% in March quarter

The company's revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

Mumbai docs try Biocon and Roche's biologic drugs on critical Covid cases

Two repurposed drugs for rheumatoid arthritis and psoriasis are being tried on over 100 patients in Mumbai

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India Inc wants govt to shift focus to economy amid Covid-19 outbreak

CEOs warn of economic depression, say need to work within new normal

Biocon gains 5% as two Bengaluru facilities receive EIR from USFDA

The stock was trading close to its all-time high level of Rs 359, touched in September 2018

Biocon, Mylan launch Fulphila, a biosimilar Pegfilgrastim in Australia

CEO of Biocon Biologics, Dr Christiane Hamacher said, Fulphila, co-developed by Biocon Biologics and Mylan, is the third biosimilar to be commercialised in Australia

Malaysia plant boosts Biocon prospects in US and other key markets

Firm seen benefiting from operating leverage, biologic sales by FY22

Biocon's US prospects get a boost after company receives EIR from USFDA

The insulin patent win, clearance of Malaysian unit and oncology biosimilar filing are triggers

Biocon gains 5% as manufacturing unit in Malaysia gets EIR from USFDA

Biocon Sdn Bhd, a subsidiary of Biocon, received the EIR from the USFDA for the pre-approval inspection of its insulin manufacturing facility in Malaysia, for insulin glargine

Build to last

In the second part of a series, the author notes down some lessons for start-ups

Biocon: Fresh biosimilar opportunities to give a boost to its US prospects

The insulin patent win and filing of another oncology biosimilar in the US to drive earnings

Biocon receives EIR from USFDA for good manufacturing practice inspection

"We remain committed to global standards of quality and compliance," company spokesperson said

Biocon, Mylan win patent case for insulin device against Sanofi in US

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

Biocon partner's Cancer drug licence application gets USFDA approval

The application sought approval of Mylan's drug for treatment of patients with metastatic colorectal cancer with fluorouracil-based chemotherapy

USFDA accepts Biocon-Mylan's Avastin biosimilar application for review

The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments

USFDA accepts proposed biosimilar application by Mylan, Biocon for review

The application seeks approval of Bevacizumab for the first-line and second-line treatment of patients with metastatic colorectal cancer in combination with fluorouracil-based chemotherapy